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Abstract The transcription factor p63, member of the p53 gene family, encodes for two main isoforms, TAp63 and ΔNp63
with distinct functions on epithelial homeostasis and cancer. Recently, we discovered that TAp63 is essential for in vitro
cardiogenesis and heart development in vivo. TAp63 is expressed by embryonic endoderm and acts on cardiac progenitors by a
cell-non-autonomous manner. In the present study, we search for cardiogenic secreted factors that could be regulated by
TAp63 and, by ChIP-seq analysis, identified Angiomodulin (AGM), also named IGFBP7 or IGFBP-rP1. We demonstrate that AGM is
necessary for cardiac commitment of embryonic stem cells (ESCs) and its regulation depends on TAp63 isoform. TAp63 directly
activates both AGM and Activin-A during ESC cardiogenesis while these secreted factors modulate TAp63 gene expression by a
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feedback loop mechanism. The molecular circuitry controlled by TAp63 on AGM/Activin-A signaling pathway and thus on
cardiogenesis emphasizes the importance of p63 during early cardiac development.
© 2013 The Authors. Published by Elsevier B.V.
Introduction
Early mammalian cardiogenesis require precise cross-
interactions between mesodermal and endodermal cells
through cell-autonomous and cell-non-autonomous events.
The latter depends on both neighboring and long-range signals
of secreted molecules. Cardiac myogenesis depends largely on
the instructive activity of the pharyngeal (anterior) endoderm
(Van Vliet et al., 2012). The embryonic endoderm plays an
essential role in cardiogenesis through the secretion of various
morphogens such as fibroblast growth factors (FGFs), Wnt and
transforming growth factors (TGF). The absence of one of
these molecules disrupts proper cardiogenesis (Alsan and
Schultheiss, 2002; Sugi and Lough, 1995).
Recently, we identified a role of p63, a transcription factor
of the p53 gene family, in murine cardiogenesis and heart
development (Rouleau et al., 2011). The p63 gene encodes
for two main isoforms, TAp63 and ΔNp63 with distinct gene
expression profiling and opposite functions on epithelial
homeostasis and cancer (Vanbokhoven et al., 2011). While
TAp63 controls cell apoptosis and aging, ΔNp63 is implicated in
cell proliferation, cell adhesion (Crum and McKeon, 2010) and
mandatory for epidermal commitment of the embryonic
ectoderm during the embryonic skin formation (Koster et al.,
2004; Shalom-Feuerstein et al., 2011). We found that p63 null
mice suffer from severe congenital cardiopathy and demon-
strated that TAp63 is an endodermal transcription factor that
controls, in a cell-non autonomous manner, cardiac differenti-
ation of embryonic stem cells (ESC) (Rouleau et al., 2011).
Accordingly, the END2 cell line that is derived from embryonic
mouse endoderm and displays cardiogenic activity (Beqqali et
al., 2006), expresses endogenous TAp63. Absence of TAp63 in ES
cells did not interfere with the commitment of mesocardiac
progenitors (mesP1+) but prevented further differentiation of
cardiac progenitors to mature cardiomyocytes (Rouleau et al.,
2011).
Here we identified a new molecular circuitry by which
endodermal TAp63 controls cardiogenesis. We show for the
first time that Angiomodulin (AGM), also known as IGFBP7 or
IGFBP-rP1, a secreted protein that regulates cellular prolifer-
ation (Nousbeck et al., 2010), adhesion, and angiogenesis (Duan
et al., 2010), is necessary for ESC cardiogenesis and that its
expression is modulated by a strict feedback loop orchestrated
by TAp63 isoform and Activin-A.
Material and methods
Cell lines
All cell lines were cultivated at 37 °C in 5% CO2. The mouse
CGR8 embryonic stem cell line, the ES sh-p63 clones and the
culture condition used in this study have been described
previously (Medawar et al., 2008). END2 cells were maintained
as described previously (Rouleau et al., 2011). HeLa and C2C12
cells were maintained in Dulbecco's modified Eagles' medium
supplemented with 10% fetal bovine serum.
Cardiomyocyte differentiation of mES cells
mES cells were cultured in the presence of 2.5 ng/ml BMP2
(Peprotech) in regular FCIII (Hyclone) medium for 2 days.
Then the cells were trypsinized and placed in hanging drops
containing 500 cells in 20 μl in differentiation medium
(DMEM supplemented with 20% FCS serum (FCII, Hyclone),
1 mM non-essential amino acids, 1 mM Sodium Pyruvate,
0.1 mM β-mercaptoethanol and 2.5 ng/ml BMP2). The drops
were placed on the lids of bacteria Petri dishes filled with
PBS. After 3 days, the embryonic bodies (EBs) formed in the
hanging drops were collected and resuspended in 5 ml
medium in 60 mm bacteriological Petri dishes and cultivated
for further 2 days in suspension. At day 5 of the differenti-
ation, 8–10 EBs were plated onto one well of gelatin-coated
24 well plates or on cover slips for immunofluorescence
staining in differentiation medium without serum, for
another 5 days. siRNA transfection targeting AGM (50 nM)
was performed 2 days before hanging drop formation, and
on day 5 of the differentiation using lipofectamin RNAiMAX
(Invitrogen). Recombinant AGM (1 μg/ml, R&D systems) was
added at day 0 of cardiomyocyte differentiation for 3 days.
For Activin A treatment, ESCs were treated from 1 day
before differentiation and during the entire differentiation
process with 5 ng/ml Activin A (R&D) (Rouleau et al., 2011).
For cardiomyocyte differentiation on END2 cells, END2 cells
treated with siRNA against TAp63, AGM or si scramble as a
control using lipofectamin RNAiMAX (Invitrogen). Sh-p63 ES
cells (Rouleau et al., 2011) seeded on END2 treated cells on
day 5 of the differentiation or on gelatin coated plates as a
control.
ChIP-seq and ChIP-qPCR analysis
Cells were cross-linked for 10 min at room temperaturewith 1%
(v/v) formaldehyde and quenched with 125 mM glycine.
Chromatin was sonicated to 200–500 bp using a Bioruptor
sonicator (Diagenode) for 15 min at high power, 30 s ON, 15 s
OFF. The chromatin was immunoprecipitated with 1 μg of
anti-p63mAb (4A4; Sc-8431, Santa Cruz Biotechnology). Eluted
DNA was recovered by phenol–chloroform extraction, precip-
itated with ethanol and resuspended in TE buffer. ChIP
material was analyzed by Real Time PCR using SYBR SensiMix
(Bioline) and specific primers to detect enrichment in the
denoted genomic regions. The amount of precipitated DNAwas
calculated as fold enrichment of % of input in p63 ChIP against %
of input in mIgG ChIP and normalized against a control region
(no gene region in chr15). The results expressed as ±standard
deviation from three experiments compared with the starting
input material as percentage of input. ChIP-seq analysis
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was performed on a Solexa Genome Analyzer (Illumina) as
described previously (Medawar et al., 2008).
ChIP-seq data analysis, de novo motif search
and p63scan
All 32-bp sequence reads were uniquely mapped to the
mouse genome NCBI 37 build (mm9) using ELAND (Illumina),
resulting in 24 million unique mapped reads. Peak recogni-
tion was performed using MACS (Zhang et al., 2008) with
default settings using a dynamic local lambda as background
and a p-value threshold of 1E-05, 1E-07, and 1E-09, giving
22,103, 15,524, and 11,329 peaks, respectively. p63 binding
peaks were mapped to RefSeq genes, downloaded from
the UCSC Genome Browser (mm9), to determine genomic
location. The ChIP-seq data and associated peaks have been
deposited in NCBI's Gene Expression Omnibus (Edgar et al.,
2002).
A de novo motif prediction pipeline combining three motif
prediction tools, MotifSampler (Thijs et al., 2001), Weeder
(Pavesi et al., 2004), and MDmodule (Liu et al., 2002), was run
on 2265 (20%) randomly selected 200-bp peak sequences
(centered at the peak summit as reported by MACS) and
PWMs were generated (van Heeringen and Veenstra, 2011). We
used the ‘large’ analysis setting for Weeder. The remaining
settings were similar as described previously (Kouwenhoven et
al., 2010). The previously established p63 motif prediction
tool, p63scan, was used to identify p63 motifs in the detected
p63 binding sites (Kouwenhoven et al., 2010).
Antibodies, immunofluorescence and FACS analysis
Immunoblotting, FACS, and immunofluorescence analysis have
been described previously (Rouleau et al., 2011; Medawar et
al., 2008). The primary antibodies used for immunofluores-
cence are mouse anti IGFBP7 (R&D), rabbit anti p63 (abcam
ab53039) and mouse anti TroponinT2 (clone Ab-1, MS-295-PO,
LabVision) following by Alexa-488 anti-mouse, Alexa 546
anti-mouse and anti Alexa 488 anti-rabbit as secondary
antibodies (Invitrogen). Images were taken by Zeiss LSM 710
confocal microscope. TroponinT2 antibody was used also for
FACS analysis following by Alexa-488 anti-mouse as secondary
antibody (Invitrogen). FACS analysis samples were analyzed
with CellQuest on FACScalibur (Becton Dickinson).
RNA extraction and real-time PCR analysis
Total RNA was isolated using Aurum RNA kit (Biorad, Hercules,
CA, USA) according to manufacturer's instruction followed by
iScript kit (Biorad) for single strand cDNA synthesis. qRT-PCR
was performed using SYBR SensiMix (Bioline, London, UK). Each
gene was amplified using the appropriate specific primers and
normalized against GAPDH.
Transfections and treatments in vitro
END2 and HeLa cells were seeded in 30% confluency, and
transfected with siRNA to AGM (50 nM) using lipofectamin
RNAiMAX (Invitrogen) and incubated for 3 days. Overexpres-
sion of TAp63 was induced in END2 cells by transfection of
pCDNA3 plasmid encoding TAp63γ (Rostagno et al., 2010)
using JetPEI reagent (Polyplus transfection). RNA extractions
were performed as described above.
Immunoprecipitation
END2 and HeLa cell lines were seeded in 50% confluency in 5%
FCS medium and transfected using lipofectamin RNAiMAX
reagent (Invitrogen) for 48–72 h with siRNA to AGM (50 nM).
Alternatively, HeLa and END2 cells were transfected using
JetPEI reagent (Polyplus transfection) with pCDNA3.1 plasmids
cloned with TAp63γ-expressing insert (Rostagno et al., 2010).
Conditioned media were collected from each well and
incubated with protein A beads (BioRad) pre-coated with
anti-AGM (R&D Biosystems, 5 μg/sample). Cell lysis (celLytic,
Sigma) and total protein concentrations were determined
to confirm equal numbers of cells in each well. Purified
precipitated proteins were resolved by 12% acryl amide gel
electrophoresis under reducing conditions, transferred onto
nitrocellulose membranes, and blocked with 5% milk (powder
from BioRad). Membranes were immunoblotted with anti-AGM
(R&D Biosystems), followed by anti-mouse HRP.
Luciferase assay and plasmids
A 209 bp sequence which contains p63-binding site segment
from the region of Activin enhancer (identified as bound by p63
by Chip-seq analysis) and 158 bp sequence lacking the p63
binding site were isolated by PCR and sub-cloned into a
luciferase reporter pGL2-basic vector (Promega) to generate
pGL2-Activin and pGL2-Activin-del plasmids respectively.
189 bp of AGM enhancer which contains p63 binding site as
well as 183 bp that lacks the p63 binding site were isolated by a
PCR and sub-cloned into a luciferase reporter pGL3-ptomoter
vector (Promega). Luciferase constructs were co-transfected
into HeLa cells along with expression plasmids encoding for
TAp63γ or ΔNp63α isoforms using JetPEI reagent (Polyplus
transfection). Protein lysates were extracted 24 h later with a
Dual Luciferase kit (Promega) and reporter assays were
performed according to manufacturer's instruction. Plasmid
pRL-SV40 (Promega) encoding Renilla luciferase served as an
internal control. Firefly luciferase activity was normalized to
Renilla luciferase activity in the same cell extract and plotted as
a ratio of firefly/Renilla luciferase activity.
Real time primers
mGAPDH for CCGGGAAACTGTGGCGTGATGG
mGAPDH rev AGGTGGAGGAGTGGGTGTCGCTGTT
mIGFBP7 for GAGCAAGGTCCTTCCATAGTG
mIGFBP7 rev CCGATGACCTCACAGCTCAAG
mMesp1 for GCGACATGCTGGCTCTTCTA
mMesp1 rev TGGTATCACTGCCGCCTCTTCC
mTnT2 for CGGAAGAGTGGGAAGAGACAAAGAACG
mTnT2 rev GCACGGGGCAAGGACACAAG
mBrachyury for GACTTCGTGACGGCTGACAA
mBrachyury rev CGAGTCTGGGTGGATGTAG
mActivin A for CGGAAGAGTACCTGGCACAT
mActivin A rev CTTCTTCCCATCTCCATCCA
mNkx2.5 for TTACCCGGGAGCCTACGGTG
(continued on next page)
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Real time primers
mNkx2.5 rev GCTTTCCGTCGCCGCCGTGCGC
mα-Actinin for CACTGAAGCCCCGCTGAACG
mα-Actinin rev TCGCCAGAATCCAGAACAATGC
mIslet1 for GCAGCAACCCAACGACAAAACTA
mIslet1 rev TATCTGGGAGCTGCGAGGACAT
mMef2c for AGATACCCACAACACACCACGCGCC
mMef2c rev ATCCTTCAGAGAGTCGCATGCGCTT
mTAp63 for CCAGAGGTCTTCCAGCATA
mTAp63 for TTTCGGAAGGTTCATCCAC
mBrachyury for GACTTCGTGACGGCTGACAA
mBrachyury rev CGAGTCTGGGTGGATGTAG
mSox17 for CGAGCCAAAGCGGAGTCTC
mSox17 rev TGCCAAGGTCAACGCCTTC
mFoxa2 for CCCTACGCCAACATGAACTCG
mFoxa2 rev GTTCTGCCGGTAGAAAGGGA
mGATA4 for TCCCCACAAGGCTATGCATCT
mGATA4 rev CCCGGAACACCCATATCCTAAG
mAFP for CCACGTTAGATTCCTCCCAGTGCGT
mAFP rev CATACTTGTTAGAGAGTTCCGTCTC
mVimentin for ACCGCTTTGCCAACTACAT
mVimentin rev TTGTCCCGCTCCACCTC
mSox-7 for GCTCCTGCTTTTGGTGTAGC
mSox-7 rev GTCCTTGGGCAGTCATTCAT
ChIP PCR primers
mNo-gene (chr15) for TGGTAGCCTCAGGAGCTTGC
mNo-gene (chr15) rev ATCCAAGATGGGACCAAGCTG
mgen_p21 for CCTTTCTATCAGCCCCAGAGGATACC
mgen_p21 rev GGGACGTCCTTAATTATCTGG GGTC
mgen_IGFBP7_for ACCCCTAGCCTCGATACCAT
mgen_IGFBP7_rev GCCTCAGGGTAAGCAACTTT
mgen_INHBA for ACTGCCAATCTGTGGGGACC
mgen_INHBA rev AAACAATGGCATTCCTTTCAAATGGC
Cloning primers
IGFBP7_prom for GCTGTTAGGGCTCAAGAGGA
IGFBP7_prom rev TGGAAGGCATTAATCATCAGC
IGFBP7_prom_del for TGCACATGGATGGTAACTAGGA
IGFBP7_prom_del rev CGCAGCAGGAGGTATTGAA
ActivinA_prom for AATGGAGTTGGCAAAGGATG
ActivinA_prom rev CCCAGGACCACACTAACCTG
ActivinA_prom_del for TTTAAACAAAAATGCTGGGAGTC
ActivinA_prom_del rev GCACACAGATGTGTTAATACCG
Results
TAp63-target genes in endodermal cells
Isolated from embryonic carcinoma, END2 cells are a mix of
visceral and parietal embryonic endoderm (Brown et al., 2010)
(see Suppl Fig. 2B for endodermal gene profile of END2 cells).
They express variable amount of TAp63 but at low level for
genomewide analysis (Rouleau et al., 2011) (Suppl. Fig. 2A). To
search for secreted endodermal cardiogenic factors driven by
TAp63, a ChIP-seq analysis was performed on the endodermal
END2 cells transfected by TAp63. To identify genome-wide
TAp63-binding sites, we utilized the model-based analysis
of ChIP-seq (MACS) peak detection algorithm (Kouwenhoven
et al., 2010). With the p-value of 1E-09, 11,329 peaks were
identified, including two well-characterized constitutive
p63-binding sites near p21 and MDM2 (Suppl. Fig. 1A). The
de novo motif prediction pipeline, GimmeMotifs revealed
a p63-binding motif similar to those previously described
(Kouwenhoven et al., 2010) (Fig. 1A). Detection of the p63
motif using p63scan showed that 97.18% of the detected peaks
were found to contain the p63-binding motif, indicating that
most of the detected peaks identified in this ChIP-seq were
directly bound by p63. A large number of the detected peaks
are located within genes (5164 peaks), whereas 1006 peaks
were found in the transcription start site (TSS) flanking region,
between −5 kb up to the end of the first intron of the gene
(Fig. 1B). A total number of 5845 genes that are potentially
regulated by p63 were identified by mapping binding sites to
the closest genes. Ingenuity Pathway Analysis (IPA, Ingenuity®
Systems) of these potential target genes revealed ‘cardiovas-
cular system development and function’ as the most enriched
Gene Ontology (GO) term (Fig. 1C) and ‘Factors Promoting
Cardiogenesis in Vertebrates’ pathway as one of the enriched
pathways (Fig. 1D). Interestingly these terms were absent from
human keratinocyte ChIP seq IPA analysis (Supplementary
Fig. 1B, 19). These data show that p63 may regulate different
sets of target genes in endodermal and epithelial cells, and this
observation strengthens our hypothesis for the involvement of
TAp63 isoform in cardiogenesis.
AGM and INHBA genes are direct targets of TAp63
Among hundreds of target genes found to be bound
by TAp63, we identified two secreted protein-encoding
genes INHBA (encoding Activin-A, of the TGF-β family) and
Angiomodulin (AGM, also known as IGFBP-7) as potential
targets of TAp63 with a conserved consensus p63-binding
sequence located in the vicinity of the regulatory regions
of both genes (Suppl. Figs. 1C and D). We choose these two
candidates for the following reasons. First, both are
secreted molecules by endodermal cells that could transmit
the cell non-autonomous effect of TAp63 on mesocardiac
progenitor differentiation. Second, INHBA gene is known to
be essential for early cardiogenesis. Suppression of the
Activin pathway prevents the induction of mesodermal and
cardiac markers (Noseda et al., 2011) and we showed that
Activin-A could partially rescue cardiogenesis in absence of
p63 (Rouleau et al., 2011). Furthermore, although not yet
shown in heart development, AGM/IGFBP7 has been recently
found to be involved in the development of the cardiovas-
cular system and angiogenesis (Abu-Safieh et al., 2011;
Hooper et al., 2009).
Using primers that flank each genomic sequence, we
confirmed by ChIP-qPCR analysis the specific binding of TAp63
isoform on the regulatory region of INHBA and AGM genes in
END2 cells transfected with TAp63-expressing construct
(Fig. 2A). We inserted a 209 bp of p63-bound genomic region
near INHBA or a 189 bp p63-bound genomic region near the AGM
gene to a pGL-luciferase construct (INHBA-luc or AGM-luc,
respectively). Each promoter/reporter was cotransfected with
a TAp63-expressing construct along with increasing concentra-
tion of ΔNp63-expressing construct. Since ΔNp63 is known to
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bind and compete to similar motifs as TAp63, it should confirm
the specific binding and activation of TAp63 on the promoters.
As illustrated in Figs. 2B–C, the reporter expression driven by
p63-bound regions in both constructs behaved similarly and
increasing amounts of ΔNp63 diminished the TAp63-induced
activation of the respective promoter activity in a dose
dependent manner. Deletion of the p63 binding site sequences
(ΔINHBA-luc or ΔAGM-luc) prevented the activation of
the promoters by TAp63 (Figs. 2B–C). These data suggest
that TAp63 directly activates both INHBA and AGM genes. In
addition, exogenous expression of TAp63 in HeLa cells activates
further INHBA and AGM gene expression (Figs. 2D–E), suggesting
that TAp63 directly activates both INHBA and AGM genes. Since
AGM is a secreted factor, we tested by western blot its protein
level in themediumof transfected cells (Figs. 2F–G). Exogenous
TAp63 increased AGM secretion, confirming that AGM is under
the regulation of TAp63. To finally strengthen the correlation
between p63 and AGM endogenous expression we utilized the
END2 cells which are a mix of visceral and parietal endodermal
cells (Brown et al., 2010). In accordance to this cellular
heterogeneity, only a fraction of cells express TAp63 and,
interestingly, AGM is systematically detected around cells that
express p63 (Fig. 2H). Those data demonstrate a co-expression
of AGM and p63 and further suggest a regulation of AGM gene
expression by TAp63.
Angiomodulin is necessary for ESC cardiogenesis
Since no link between AGM and ESC cardiogenesis has been
reported so far, we first tested the relative expression of AGM
in ESC during cardiac fate and found that AGM gene expression
increased gradually during cardiac differentiation along with
TAp63 gene activation (Figs. 3A–B). To test a possible role of
AGM on ESC cardiogenesis, we performed siRNA experiments
to knockdown its expression (si-AGM; Suppl. Fig. 3A) in ESC
during cardiac commitment. AGM gene inhibition did not
impact significantly the relative expression of mesocardiac
early markers like Brachyury and MesP1 (Fig. 3C) but reduced
the number of beating EBs (Suppl. Fig. 3B) and cardiac-related
gene expression on day 5 and day 11 (Fig. 3C), similar to TAp63
knock down (Fig. 4A) (Rouleau et al., 2011). The reduction in
Troponin-T gene expression was also demonstrated at the
protein level by FACS analysis (Suppl. Fig. 3C) and immuno-
fluorescence staining of Troponin-T+-cells (Figs. 3D–E) at day
10 of cardiac differentiation. To confirm that AGM acts on
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Figure 1 Identification of p63-target genes by ChIP-seq analysis of END2 cells. A. p63 consensus binding motif identified from
11,329 binding sites. B. p63 binding motif distribution relative to RefSeq genes. TSS flanking region: 5 kb upstream of TSS, first exon
and first intron, intragenic: rest of the gene, b25: 5–25 kb upstream or 25 kb downstream of the last exon, intergenic: rest of the
genome. C. The Ingenuity Systems Inc. (IPA) software tool was used to examine TAp63 functional pathways. Statistical enriched
physiological system biology and function are shown. D. Top 5 canonical pathways statistically over-represented among TAp63
binding genes are shown. p-values were calculated by Fisher exact test, ratio is the number of molecules in a given pathway divided
by the total number of molecules that make up that pathway.
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cardiogenesis through p63 activation, and to test whether
AGM and Activin act in a synergistic manner, recombinant AGM
and recombinant Activin-A were added to the medium of
shp63 ES cells at day 0 of cardiac differentiation. As expected
from our previous study (Rouleau et al., 2011), absence of p63
prevented cardiogenesis. Addition of either AGM or Activin-A
was able to partially rescue cardiogenesis of shp63 ES cells, as
illustrated by increased number of beating EBs (Fig. 3F) and
increase expression of cardiac-related genes (Figs. 3G–I).
Addition of both AGM and Activin-A together enhanced further
Figure 2 INHBA and AGM are direct p63-target genes. (A). Specific binding of p63 on the regulatory region of INHBA and AGM genes
were confirmed by ChIP-qPCR analysis in END2 transfected with TAp63 plasmid, using anti-p63 (4A4) antibody. p21 and Irf6 were used
as positive controls, and irrelevant sequence from chromosome 15 used as a negative control (no gene). The fold enrichment is the
ratio of % of input in p63 ChIP against % of input in mIgG ChIP and represent mean ± SE of 3 independent experiments. (B–C).
Luciferase reporter assay for AGM (B) and INHBA (C) promoter relative activities. A fragment of the INHBA or AGM genomic region
containing the p63-binding site was inserted upstream to a pGL-luciferase construct (INHBA-luc and AGM-luc, respectively) and
cotransfected it along with TAp63 and ΔNp63 expressing constructs or empty vector as control. A promoter region in which the
p63-binding site has been deleted (ΔINHBA-luc or ΔAGM-luc) was tested as a negative control. Promoter activities are normalized to
luciferase activity of the INHBA-luc or AGM-luc promoters, respectively. Renilla plasmid was used as an internal control. Data is
represented as the average of three experiments ± SE, *p b 0.05. D–E. HeLa cells were transfected with TAp63-expressing construct
and tested for INHBA (D) or AGM (E) gene expression by qRT-PCR. Results of three independent experiments are represented as fold
change of control treatment. *p b 0.05; **p b 0.01. F. Representative western blot analysis of secreted AGM immuno-precipitated
from conditioned medium of HeLa cells transfected with constructs expressing TAp63 (or empty pCDNA vector). Relative AGM
gene expression is shown in arbitrary units quantified by ImageJ. G. Representative western blot analysis of secreted AGM
immuno-precipitated from conditioned medium of END2 cells transfected with constructs expressing empty pCDNA vector, TAp63 or
si-AGM. Relative AGM gene expression is shown in arbitrary units quantified by ImageJ. H. Immunofluorescence detection of p63
(green) and AGM (red) in END2 cells showed co-expression of p63 and AGM. Yellow arrows indicate negative cells for TAp63 which are
also negative for AGM. DAPI staining is shown in blue. Scale bar = 10 μm.
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cardiogenesis. To further demonstrate that cardiogenesis
depends on both endodermal TAp63 and AGM endodermal
gene expression, we cultivated shp63 EBs, which have
impaired the ability to undergo cardiomyocyte differentiation
(Rouleau et al., 2011), on fixed END2 cells which were
prior treated with siRNA against TAp63, AGM or scramble as
a control. END2 cells treated with si-scramble were able
to restore cardiogenesis of shp63 cells as demonstrated by the
increased number of beating EBs (Suppl. Fig. 3E) and the
increased expression of cardiac-related genes, as compared to
shp63 EBs seeded on gelatin (Fig. 3J). In contrast, END2 cells
that underwent AGM or TAp63 silencing prior to the deposition
of shp63 EBs, hardly restored shp63 cardiomyocyte differen-
tiation (Fig. 3J, Suppl. Fig. 3E). These results demonstrate
that TAp63 and AGM expressed by endodermal cells are
essential to cardiogenesis regulation. Both AGM and Activin-A
also play a role during vascular development. Thus, we tested
whether vascular endothelium fate could be altered by the
absence of p63 or AGM. The results show that the expression of
vascular markers Flk1 and CD31 was not significantly modified
in the absence of p63 or AGM (Suppl. Fig. 3D). Altogether,
these data suggest that Activin-A and AGM act in a synergistic
way on cardiogenesis. It demonstrates for the first time a role
for AGM during ESC cardiogenesis, partially through p63
cascade.
Regulatory network between Activin-A and AGM is
crucial for cardiogenesis and modulate p63
expression in a feedback loop
The direct regulation of AGM and INHBA genes by TAp63 does
not exclude reciprocal interaction between them during ESC
cardiogenesis. To further explore the feedback interplay
between TAp63 isoform, AGM and INHBA, we tested the direct
role of INHBA during ESC cardiac commitment. Treatment of ES
cells by SB431542, a pharmacological inhibitor of activin/nodal
pathway, reduced cardiogenesis (Cai et al., 2012) (Fig. 4A).
This inhibitory effect of SB431542 on cardiogenesis is amplified
in differentiated ES cells in which p63 (si-TAp63) or AGM
(si-AGM) has been silenced (Fig. 4A). These data suggest that
TAp63 controls cardiogenesis by two synergistic AGM and INHBA
pathways (Fig. 5). Previously, we have shown that ES cells in
which p63 gene had been silenced (shp63) barely undergo
cardiogenesis and that the addition of Activin-A could rescue it
(Rouleau et al., 2011). To test a potential regulation of AGM by
Activin-A, WT ES cells and shp63 ES cells were treated with
recombinant Activin-A during cardiac commitment and AGM
gene expression was measured at day 9 (Fig. 4B). In addition to
its ability to rescue cardiogenesis (Suppl. Fig. 4), Activin-A was
able to efficiently activate AGM gene expression (Fig. 4B).
Interestingly, the level of AGM expression in shp63 ES cells
treated by Activin-A exceeded by far that of the treated WT ES
cells. Because of the absence of p63, the cell types present in
the WT and shp63 ES cells at day 9 of differentiation become
quite different and thus could respond differently to
Activin-A for AGM gene expression. That Activin-A reduced
cardiogenesis of WT ES cells suggests that balanced Activin
expression in an accurate amount is important for proper
signaling to promote cardiogenesis. Accordingly, it fits a
previous report that overexpression of Activin induced
inhibition of cardiac differentiation (van den Eijnden-van
Raaij et al., 1991). These data demonstrate that p63
controls cardiogenesis by overlapping but different path-
ways, regulating AGM and INHBA in direct and indirect
manners (Fig. 5).
Figure 2 (continued).
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We further tested whether AGM and INHBA could modulate
back their regulation by TAp63. C2C12 cells, that express
endogenous TAp63 isoform, were treated by either si-AGM or
SB431542 and tested for TAp63 gene expression (Figs. 4C–D).
Inactivation of AGM enhanced TAp63 (Fig. 4C). This regulatory
loop was also found for Activin-A as its inhibition by SB431542
enhanced TAp63 expression (Fig. 4D). All these data demon-
strate that TAp63 isoform regulates AGM gene directly but also
indirectly through themodulation of the INHBA gene expression
and that both INHBA and AGM can control their modulators by a
feedback loop mechanism, balancing their required expression
for proper function (Fig. 5).
Discussion
We have recently reported that the gene p63 is a new actor of
early cardiac differentiation (Rouleau et al., 2011). Its main
isoform TAp63 is expressed by embryonic endodermal cells
to regulate cardiac differentiation of mesocardiac progenitors.
As the effect of TAp63 on cardiogenesis occurs in a cell
non-autonomous manner, we searched for secreted molecules
that could be under the regulation of TAp63 pathway in
endodermal cells and related to cardiogenesis. We identified
Angiomodulin (AGM) as a direct target of TAp63 regulation
during ESC cardiogenesis. Angiomodulin, also known as mac25,
Figure 3 AGM is necessary for ESC differentiation into cardiomyocytes. A. AGM gene expression was monitored during cardiac
differentiation of ES cells by qRT-PCR. Data represent the average of three independent experiments ± SE. B. TAp63 gene expression
was monitored during cardiac differentiation of ES cells by qRT-PCR. Data represent the average of three independent experiments ±
SE. (C). ES cells were treated with siRNA against AGM (or scramble as control) and cardiogenesis was monitored for cardiac-related
gene expression by real time PCR analysis at day 5 (Islet1) or day 10. Data represent the average of three independent experiments ±
SE. *p b 0.05. D. Immunofluorescence staining for Troponin-T at day 10 of cardiomyocyte differentiation of ES cells treated with
si-scramble or si-AGM. E. Relative fluorescence of Troponin T staining of different areas of (D) was quantified using ImageJ. Data
represent the average of six different pictures ± SE. * p b 0.01. F. Ratio of beating areas within the EBs at day 11 of cardiomyocyte
differentiation of sh-p63 ES cells in the presence of recombinant AGM, Activin or both. Data represent the average of two
independent experiments ± SE. **p b 0.01. G–I. Expression of cardiac-related markers analyzed by qRT-PCR, at days 6 (G–H) and 11
(I), of sh-p63 ES cells that were induced to cardiomyocyte differentiation in the presence of recombinant AGM, recombinant Activin-A
or both. Data represent the fold change of untreated cells normalized to day 0 of the differentiation.*p b 0.05, **p b 0.01. J. Real
time PCR analysis of cardiac-related markers expressed on day 11 of cardiomyocyte differentiation of shp63 EBs cultivated on gelatin
or on END2 feeder cells which have been treated with siRNAs against TAp63, AGM or with scrambled siRNAs as control. Data represent
the fold change of cells seeded on gelatin normalized to day 0 of the differentiation. Data show the summary of two independent
experiments ± SE, *p b 0.05.
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IGFBP7 or IGFBP-related protein-1 (IGFBP-rP1) is a secreted
protein belonging to the IGFBP family (Duan et al., 2010). AGM/
IGFBP7 is known as a tumor suppressor gene for a variety of
cancers (Wajapeyee et al., 2009), particularly in melanoma
progression but also involved in skin pathophysiology (Nousbeck
et al., 2010). Recently, IGFBP7 has been linked to the
development of the cardiovascular system and angiogenesis.
First, a germlinemutation on AGM gene in humans was shown to
lead to obstruction of the right ventricular outflow tract, a
phenotype similar to that of the p63 KOmice (Abu-Safieh et al.,
2011). Second, AGM inhibits vascular endothelial growth factor
(VEGF)-induced angiogenesis (Hooper et al., 2009). Here we
demonstrated that inhibition of AGM gene expression partially
prevents ESC cardiogenesis. It validates that ChIP-seq analysis
made on transfected cells, when endogenous transcription
factor is lowly expressed, could mimic physiological conditions.
We believe that AGM/IGFBP7 functions during advanced stages
of cardiac ESC differentiation, as early mesocardiac markers
were not affected by its inhibition. To our knowledge, our
study is the first to demonstrate a role of AGM/IGFBP7 on
cardiogenesis. However, no developmental defect, including
cardiac phenotype, has been reported in IGFBP7 KO mice
(unpublished data from A. Seth). This could be due to gene
compensation by other members of the IGFBP family. As a
matter of fact, IGFBP-4 enhances cardiomyocyte differentiation
both in vitro and in vivo (Zhu et al., 2008).
IGFBPs regulate the bioavailability of IGFs by binding to
IGFs with high affinity thereby limiting IGF access to
IGF-IR and inhibiting IGF activity (Duan et al., 2010).
However, IGFBP7 differs from the other six members of
this family by having considerably lower affinity for IGF-I.
Instead, it binds strongly to insulin and blocks insulin
action. Interestingly, it has been reported that insulin
strongly inhibits cardiac differentiation of ES cells by
suppressing mesodermal fate (Freund et al., 2008)
through IGF-R activation (van den Eijnden-van Raaij et
al., 1991). Thus, when secreted by endodermal cells
under the control of TAp63, AGM/IGFBP7 may activate ESC
cardiogenesis by blocking insulin interaction with IGF-R on
mesocardiac precursors to allow their normal cardiac
commitment.
In addition to AGM, we identified Activin-A as a direct
target gene of TAp63 regulation during ESC cardiogenesis.
Activin-A, of the TGF-β family, is known to be essential for
early cardiogenesis. Endodermal and mesodermal cells
secrete it at early stages of mouse and human develop-
ment (Brown et al., 2010). Suppression of the Activin
pathway prevents the induction of mesodermal and
cardiac markers. Interestingly it has been reported that
over expression of Activin induced the inhibition of cardiac
differentiation (van den Eijnden-van Raaij et al., 1991),
demonstrating that balanced Activin expression in an
accurate amount is important for proper signaling to
promote cardiogenesis. Still, its regulation in the course
of early cardiogenesis by the instructive endoderm is
not fully known. Here we show that TAp63 directly
activates both AGM and Activin-A, and that their synergic
production under TAp63 control is necessary for proper
cardiogenesis (Fig. 5). Consequently, ESC cardiogenesis
partially depends on both AGM and Activin-A reciprocal
Figure 3 (continued).
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activation. AGM/IGFBP-7 has been widely reported as a
p53-responsive gene in many tumors (Suzuki et al., 2010)
but was never related to p63.
In addition, we demonstrated that Activin-A activates
efficiently AGM gene expression independently of p63 during
cardiogenesis of ES cells. Furthermore, our data suggest a
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Figure 4 Feedback regulation of p63 isoforms by Activin-A and AGM. A. ES cells were pretreated as hanging drops with siRNAs
against TAp63, AGM or with scrambled siRNAs as control and induced to cardiogenesis in the presence of DMSO (vehicle control) or the
activin/nodal inhibitor SB431542 (10 μM from day 5). Cardiac differentiation was measured at day 9 by qRT-PCR using cardiac-related
markers. The results are presented as percentage of control. Data show the summary of three independent experiments ± SE,
*p b 0.05. B. WT and shp63 ES cells were induced to cardiac differentiation in the presence (+) or absence (−) of recombinant INHBA
and analyzed by qRT-PCR for AGM gene expression at day 9. Data show the summary of three independent experiments ± SE,
**p b 0.01. C–D. TAp63 gene expression of C2C12 cells after transfection with si-AGM (C) or treatment with SB431542 (D) analyzed by
qRT-PCR. Data show summary the of three independent experiments ± SE, *p b 0.05 and ** p b 0.01.
TAp63TAp63 Activin
Cardiogenesis
Endoderm
AGM
Mesoderm
Figure 5 Model of feedback loop network between TAp63, AGM and INHBA for ESC cardiogenesis. The diagram summarizes the data
presented in this study. TAp63 regulates both AGM and INHBA (activin-A) genes for proper cardiogenesis. These effects are modulated
by feedback loop of AGM and INHBA on TAp63.
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negative feedback regulation of TAp63 gene by AGM and
Activin-A (Fig. 5). These feedback regulations may be necessary
to modulate cardiogenesis activation by endodermal TAp63. In
conclusion, we demonstrate that both INHBA and AGM are
controlled by TAp63 during ESC cardiogenesis and can control
their modulator by a feedback loop mechanism (Fig. 5).
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